Oritavancin compared against vancomycin for skin infections

09/10/2013 | SkinAndAllergyNews.com

The effectiveness of single-dose intravenous oritavancin was similar to that of seven- to 10-day treatment with intravenous vancomycin for acute bacterial skin and skin structure infections, a multicenter study found. The most common adverse events reported in the oritavancin group included nausea, diarrhea and headache. Oritavancin was "well-tolerated, with a safety profile similar to vancomycin," lead author Dr. G. Ralph Corey reported at the Interscience Conference on Antimicrobial Agents and Chemotherapy.

View Full Article in:

SkinAndAllergyNews.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR